share_log

中恒集团(600252.SH):控股子公司丙氨酰谷氨酰胺注射液获得药品补充申请批准通知书

Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary, the injection of N-acetylglycylglutamine, has obtained the supplementary application approval notice for pharmaceuticals.

Gelonghui Finance ·  Nov 26, 2024 18:39

On November 26, Gelonghui reported that guangxi wuzhou zhongheng group (600252.SH) announced that its holding subsidiary chongqing lummy pharmaceutical co., ltd. (referred to as "lummy pharmaceutical") received the approval issued by the National Medical Products Administration for the supplemental application approval notice of 50ml: 10g and 100ml: 20g specifications of L-Alanyl-Glutamine injection. L-Alanyl-Glutamine injection is a dipeptide nutritional solution developed by the German Fresenius company, marketed as Dipeptiven. This pharmaceutical is part of clinical nutrition regimens and is suitable for patients requiring glutamine supplementation via parenteral nutrition, including those in catabolic and hypermetabolic states.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment